Roche

News

Price cut unlocks NICE nod for Perjeta in post-surgery breas...

Roche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer from recurring after surgery, at the third attempt.

News

Pharma companies clear the R&D decks in Q4

The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies' pipelines as they tighten their focus on the projects with the most chance of a

Views & Analysis

R&D roundup: the ups and downs of CRISPR and Alzheimer’s

While the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm has announced that it is licensing back two gene editing compounds that can

News

Roche seeks Kadcyla boost to fend off Herceptin biosimilars

As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla.

Views & Analysis

The future of patient value

Ahead of the 2019 eyeforpharma Barcelona conference, we asked speaker and awards judge Heather Moses – head of medical affairs at Roche – what she is looking for in winning patient init

News

Roche cancels two phase III Alzheimer’s trials

Roche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim analysis indicated it would not hit its primary endpoint.

Price cut unlocks NICE nod for Perjeta in post-surgery breas...

Pharma companies clear the R&D decks in Q4

R&D roundup: the ups and downs of CRISPR and Alzheimer’s

Roche seeks Kadcyla boost to fend off Herceptin biosimilars

The future of patient value

Roche cancels two phase III Alzheimer’s trials

AI specialists Enveda and Basecamp rake in the cash

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks